GlassScriptPhysician profile
Peter C Fenton
NPI 1952311797
$2,605.36
in general payments reported to CMS, 2019-2025
31 companies · $872 in 2025
The $872 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $247 · 2021: $288 · 2022: $145 · 2023: $293 · 2024: $235 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351 · Education: $50.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,350.63 |
| Education | $50.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $548.96 | 2019-2025 | |
| Janssen Biotech, INC. | $539.13 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $341.33 | 2019-2025 | Entyvio |
| E.R. Squibb & Sons, L.L.C. | $130.24 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.41 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $85.44 | 2019-2024 | |
| Pfizer INC. | $77.92 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $70.29 | 2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $60.84 | 2025 | Dupixent |
| Lilly USA, LLC | $58.38 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $53.30 | 2025 | Rezdiffra |
| Qol Medical, LLC | $51.16 | 2019-2025 | Sucraid |
| Boston Scientific Corporation | $46.47 | 2021 | |
| Genzyme Corporation | $44.51 | 2024 | |
| Shire North American Group INC | $37.31 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $35.40 | 2019-2020 | |
| Ardelyx, INC. | $35.28 | 2024-2025 | Ibsrela |
| Organon LLC | $34.38 | 2024-2025 | Hadlima |
| Orphalan INC | $31.89 | 2025 | Cuvrior |
| Capsovision, INC. | $28.08 | 2025 | Capsocam Plus |
| Pharming Healthcare, INC. | $26.34 | 2023 | Ruconest |
| Celltrion USA INC. | $23.76 | 2025 | Vegzelma |
| Allergan, INC. | $23.52 | 2019 | |
| Ferring Pharmaceuticals INC. | $22.03 | 2025 | Rebyota |
| Celgene Corporation | $17.61 | 2023 | Zeposia |
| Ucb, INC. | $14.63 | 2019 | |
| Biocon Biologics INC | $14.39 | 2025 | Yesintek |
| Redhill Biopharma INC. | $14.14 | 2021 | |
| Alfasigma USA, INC. | $12.93 | 2020 | |
| Phathom Pharmaceuticals, INC. | $11.29 | 2025 | Voquezna |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,973.95 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Fenton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.